- Scinai Immunotherapeutics has ended its option and license arrangements with PinCell relating to PC111 after the applicable option conditions expired on August 31, 2026.
- The company will focus its R&D resources on its NanoAb platform while supporting the growth of its CDMO business, which had approximately $3.1 million in committed customer orders as of August 16, 2026.
Scinai Immunotherapeutics Ltd. has ended its option and license arrangements with PinCell S.r.l. relating to PC111 and will refocus its R&D resources on its NanoAb platform and its contract development and manufacturing organization (CDMO) business. The applicable option conditions expired on August 31, 2026, after discussions between the companies did not result in an extension. Scinai said the decision was not driven by a new negative scientific finding regarding PC111.
The company said it will prioritize its NanoAb platform, which uses VHH antibody fragments to develop mono-, bi- and multi-specific therapeutic formats for inflammatory and immune-mediated diseases. Scinai is advancing two IL-17 programs, including an intradermal IL-17 program for psoriasis that is under evaluation for approximately €12 million in grant financing through Poland’s FENG program. Its systemic IL-17 bispecific program is also progressing, with in vivo proof-of-concept identified as the next major development milestone.
The portfolio change comes alongside commercial activity within Scinai’s CDMO business, Scinai Biopharma Services. As of August 16, 2026, committed customer orders totaled approximately $3.1 million across its Jerusalem and Yavne facilities. The company continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue-recognition criteria and conversion of additional opportunities.
Scinai has also started substantive activities under an expanded clinical manufacturing and chemistry, manufacturing and controls (CMC) program for a U.S.-based biopharmaceutical customer. The program is intended to support a planned U.S. regulatory submission and subsequent Phase III development, with potential future expansion into commercial manufacturing. The broader scope and commercial terms remain under negotiation.
“The company’s priorities are to advance its NanoAb portfolio, deliver for CDMO customers, and convert the capabilities of its two-site platform into revenue and improved operating performance. Concentrating resources on these priorities would reduce prospective near-term R&D commitments while supporting opportunities for longer-term value creation.”
Amir Reichman, CEO of Scinai
